HAMF
ENTA icon

Hatteras Alternative Mutual Funds’s Enanta Pharmaceuticals ENTA Stock Holding History

Hatteras Alternative Mutual Funds’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-58,924
Closed -$2.36M – 185
2014
Q1 		$2.36M Buy
58,924
+41,024
+229% +$1.49M 1.13% 24
2013
Q4 		$488K Buy
+17,900
New +$434K 0.27% 119

Other funds holding ENTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICRM
Insight Capital Research & Management Walnut Creek, California $177M AUM 72% 1-Year Est. Return

Hatteras Alternative Mutual Funds's ENTA Position: Q2 2014 in Review

Hatteras Alternative Mutual Funds sold out of Enanta Pharmaceuticals (ENTA) in Q2 2014, closing a stake of 58,924 shares — an estimated $2.36M sold.

Hatteras Alternative Mutual Funds first reported a position in ENTA in Q4 2013 and held it in 2 quarters. The position peaked at $2.36M in Q1 2014. 98 funds tracked by Wall St. Rank hold ENTA as of Q2 2014.

  • Hatteras Alternative Mutual Funds reported no remaining Enanta Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Hatteras Alternative Mutual Funds sold 58,924 Enanta Pharmaceuticals shares in Q2 2014, an estimated $2.36M.
  • Hatteras Alternative Mutual Funds first reported a position in Enanta Pharmaceuticals in Q4 2013 and held it in 2 quarters.
  • Hatteras Alternative Mutual Funds's Enanta Pharmaceuticals position peaked at $2.36M in Q1 2014.
  • 98 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2014.

Based on Hatteras Alternative Mutual Funds's 13F filing for Q2 2014, filed 13 Aug 2014.